FDA says knockoff versions of Lilly obesity drug must come off the market
3 weeks, 1 day ago

FDA says knockoff versions of Lilly obesity drug must come off the market

Associated Press  

WASHINGTON — Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and diabetes will need to phase out their versions next year under a federal decision issued Thursday. With demand for GLP-1 drugs booming, compounding pharmacies and telehealth companies like Hims and Ro have jumped into the market, selling cheaper versions online. The FDA permits compounded versions of brand name drugs when they are in shortage, and the shift back to Lilly’s medications could improve safety for consumers. Compounding pharmacies use raw drug ingredients to produce customized versions of prescription medications — for instance, when patients have allergies to certain ingredients.

Drugs Drug Fda Glp Zepbound Versions Mounjaro Lilly Shortage  obesity  come  lilly  versions  drug  glp1  pharmacies  decision  shortage  mounjaro  fda  market  drugs  online  patients  knockoff

History of this topic

Why the Obesity Drug Revolution Is a Work in Progress
1 week, 2 days ago

Why the Obesity Drug Revolution Is a Work in Progress

Bloomberg  

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. It also remains unclear whether pharma companies can actually deliver on the promise of even better weight-loss drugs — part …

Why Is There So Much Off-Brand Oral Ozempic for Sale Online?
1 month, 3 weeks ago

Why Is There So Much Off-Brand Oral Ozempic for Sale Online?

Wired  

Since they debuted, injectable GLP-1 drugs like Ozempic have been in high demand. It’s an appealing prospect—especially since these drugs are offered at a fraction of the price of their name-brand counterparts and are often shipped overnight after a prospective patient fills out a quick online questionnaire. “As a pharmacist, I can appreciate the excitement in the rise in oral …

Eli Lilly and Novo want to shake off Ozempic copycats. Are they ready to meet demand?
1 month, 3 weeks ago

Eli Lilly and Novo want to shake off Ozempic copycats. Are they ready to meet demand?

Live Mint  

Pharmaceutical companies are typically rewarded for their innovation with years of market exclusivity before cheaper generics enter the scene. That window for mass drug compounding, however, could start to close if the FDA upholds its recent determination that tirzepatide, the active ingredient in Eli Lilly’s Zepbound and Mounjaro, is no longer in short supply. If the FDA moves to restrict …

Ten Americans die and 100 are hospitalized after taking Ozempic-like drugs
2 months ago

Ten Americans die and 100 are hospitalized after taking Ozempic-like drugs

Daily Mail  

Ten people have died and 100 have been hospitalized after taking pharmacy-made copycat versions of Ozempic, its manufacturer has revealed. Ozempic maker Novo Nordisk claims these off-brand versions of its drugs are made with little regulation or oversight which raises the risk that someone could fall ill after using them. Novo revealed the cases after asking the FDA to ban …

The Crackdown on Compounded GLP-1 Meds Has Begun
3 months ago

The Crackdown on Compounded GLP-1 Meds Has Begun

Wired  

Eli Lilly has sent cease-and-desist letters to hundreds of compounding pharmacies, telehealth companies, and medical spas making and selling “compounded” versions of tirzepatide. Eli Lilly specifically accused this oral tirzepatide seller of “experimenting” on its customers, noting that the US Food and Drug Administration has not approved any oral tirzepatide medications. Eli Lilly also targeted at least one weight-loss clinic …

Lilly weight-loss drug copycats dealt blow as shortage ends
3 months, 1 week ago

Lilly weight-loss drug copycats dealt blow as shortage ends

LA Times  

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S. Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines. The Food and Drug …

It’s survival of the fittest for brands trying to get in on the Ozempic weight-loss industry
5 months, 3 weeks ago

It’s survival of the fittest for brands trying to get in on the Ozempic weight-loss industry

LA Times  

Before he began taking Mounjaro last summer, Nick Lovell was the weight-loss economy’s ideal customer. — Dr. Gary Foster, chief scientific officer at WeightWatchers Atkins, a WeightWatchers rival, also wants a bite of the lucrative market and has adopted similar language: We’re “your ally in a new era of weight loss,” the low-carb diet program says on a dedicated GLP-1 …

WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs
6 months, 3 weeks ago

WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs

Associated Press  

The World Health Organization and drugmaker Eli Lilly and Co. are warning people to be wary of fake versions of popular weight-loss and diabetes medicines. WHO said Thursday that it has fielded several reports of fake semaglutide — the active ingredient in Novo Nordisk’s Wegovy and Ozempic — in all geographic regions of the world since 2022. Lilly said in …

WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs
6 months, 3 weeks ago

WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy The World Health Organization and …

Pharma's mess of its own making — greed, secrecy and weight-loss drugs
7 months, 2 weeks ago

Pharma's mess of its own making — greed, secrecy and weight-loss drugs

ABC  

How does that saying go? That seems to be the current predicament for Australia's compounding pharmacists, who were this week completely banned from making replica versions of the diabetes drugs Ozempic and Mounjaro. The ABC uncovered patients with side effects linked to one rogue compounding pharmacist in Sydney who managed to illegally manufacture and export replicas of the popular weight …

GNC is struggling. It hopes Ozempic can give it a boost
8 months, 1 week ago

GNC is struggling. It hopes Ozempic can give it a boost

CNN  

New York CNN — GNC, the vitamin and dietary supplement chain, has been struggling for years. The brand hopes a new strategy tailored to people taking GLP-1 drugs for weight loss will help draw customers into stores and grow its business. GNC announced Monday that it was adding a dedicated section in its 2,300 US stores with vitamins, protein shakes …

"Faux-zempic": Behind the rise in fake weight loss drugs that are hospitalizing some people
11 months, 3 weeks ago

"Faux-zempic": Behind the rise in fake weight loss drugs that are hospitalizing some people

Salon  

When Lucy, a psychiatrist practicing in the Northeast, saw one of her patients after she started using Ozempic, a drug that has exploded in popularity in recent months, she could tell that something was off. “It gave me this motivation that this is really going to work, I'm feeling myself and I can start exercising again.” “When even your own …

Big Pharma scrambles to feed demand for weight-loss treatments amid rising US obesity rates
1 year, 1 month ago

Big Pharma scrambles to feed demand for weight-loss treatments amid rising US obesity rates

Associated Press  

NEW YORK — Obesity rates in the U.S. have been rising steadily for well over a decade and some of the world’s biggest drug developers are tapping into the growing treatment market. It notably priced the drug at roughly a 20% discount to Novo Nordisk’s Wegovy as the companies try to entice more employers to include weight-loss drugs in their …

Discover Related